The committee will discuss NDA 22-308, besifloxacin ophthalmic solution (Bausch & Lomb), proposed for the treatment of bacterial conjunctivitis and NDA 22-369, bimatoprost ophthalmic solution, 0.03% (Allergan) proposed for the treatment of hypotrichosis of the eyelids.
